The Expression of the Beta Cell-Derived Autoimmune Ligand for the Killer Receptor Nkp46 Is Attenuated in Type 2 Diabetes

Chamutal Gur,Jonatan Enk,Efraim Weitman,Etty Bachar,Yaron Suissa,Guy Cohen,Rachel Ben-Haroush Schyr,Helena Sabanay,Elad Horwitz,Benjamin Glaser,Yuval Dor,Ariel Pribluda,Jacob H. Hanna,Gill Leibowitz,Ofer Mandelboim
DOI: https://doi.org/10.1371/journal.pone.0074033
IF: 3.7
2013-08-29
PLoS ONE
Abstract:NK cells rapidly kill tumor cells, virus infected cells and even self cells. This is mediated via killer receptors, among which NKp46 (NCR1 in mice) is prominent. We have recently demonstrated that in type 1 diabetes (T1D) NK cells accumulate in the diseased pancreas and that they manifest a hyporesponsive phenotype. In addition, we found that NKp46 recognizes an unknown ligand expressed by beta cells derived from humans and mice and that blocking of NKp46 activity prevented diabetes development. Here we investigated the properties of the unknown NKp46 ligand. We show that the NKp46 ligand is mainly located in insulin granules and that it is constitutively secreted. Following glucose stimulation the NKp46 ligand translocates to the cell membrane and its secretion decreases. We further demonstrate by using several modalities that the unknown NKp46 ligand is not insulin. Finally, we studied the expression of the NKp46 ligand in type 2 diabetes (T2D) using 3 different in vivo models and 2 species; mice and gerbils. We demonstrate that the expression of the NKp46 ligand is decreased in all models of T2D studied, suggesting that NKp46 is not involved in T2D.
multidisciplinary sciences
What problem does this paper attempt to address?